7 November 2025 - Vera Therapeutics today announced it has submitted a biologics license application to the US FDA through the accelerated approval program for atacicept for the treatment of adults with immunoglobulin A nephropathy.

The BLA submission for atacicept is supported by data from a pre-specified interim analysis of the ORIGIN 3 trial, which met the primary endpoint of reduction in proteinuria at week 36.

Read Vera Therapeutics press release